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Abstract
Objectives—To compare pre and post-ART attrition between youth (15–24 years) and other 
patients in HIV care, and to investigate factors associated with attrition among youth.
Design—Cohort study utilizing routinely collected patient-level data from 160 HIV clinics in 
Kenya, Mozambique, Tanzania, and Rwanda.
Methods—Patients at least 10 years of age enrolling in HIV care between 01/05 and 09/10 were 
included. Attrition (loss to follow-up or death 1 year after enrollment or ART initiation) was 
compared between youth and other patients using multivariate competing risk (pre-ART) and 
traditional (post-ART) Cox proportional hazards methods accounting for within-clinic correlation. 
Among youth, patient-level and clinic-level factors associated with attrition were similarly 
assessed.
Results—A total of 312 335 patients at least 10 years of age enrolled in HIV care; 147 936(47%) 
initiated ART, 17% enrolling in care and 10% initiating ART were youth. Attrition before and 
after ART initiation was substantially higher among youth compared with other age groups. 
Among youth, nonpregnant women experienced lower pre-ART attrition than men [sub-division 
hazard ratio=0.90, 95% confidence interval (CI): 0.86–0.94], while both pregnant [adjusted hazard 
ratio (AHR) = 0.85, 95% CI: 0.74–0.97] and nonpregnant (AHR = 0.79, 95% CI: 0.73–0.86) 
female youth experienced lower post-ART attrition than men. Youth attending clinics providing 
sexual and reproductive health services including condoms (AHR = 0.47, 95% CI: 0.32–0.70) and 
clinics offering adolescent support groups (AHR = 0.73, 95% CI: 0.52–1.0) experienced 
significantly lower attrition after ART initiation.
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Conclusion—Youth experienced substantially higher attrition before and after ART initiation 
compared with younger adolescents and older adults. Adolescent-friendly services were associated 
with reduced attrition among youth, particularly after ART initiation.
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Introduction
Currently, an estimated four million HIV-infected youth aged 15–24 years reside in sub-
Saharan Africa [1], and account for 20% of all people living with HIV/AIDS in the region 
[2]. With approximately 40% of all new HIV infections occurring among youth [3] and 
perinatally infected children on antiretroviral therapy (ART) aging into this group [4], this 
population is expected to grow. As young people are critical to the economic future of sub-
Saharan Africa, optimizing outcomes across the HIV care cascade among HIV-infected 
youth is a priority [5].
The transition from childhood through adolescence to adulthood often involves rapid, 
sometimes destabilizing, change that may compromise these outcomes. Youth may leave 
parental supervision to form their own families, and/or migrate for work or education. They 
may make healthcare decisions for themselves for the first time, often without sufficient 
knowledge of the importance of sustained engagement with healthcare systems. The effect 
of these and the other psychosocial, cognitive and behavioral changes that characterize this 
period is reflected in the emerging literature on HIV-related outcomes among young people. 
Several studies in sub-Saharan Africa have shown that when compared with adults 25 years 
and older, youth are substantially less likely to know their HIV status [6–9], and youth in 
sub-Saharan Africa have been found to lack basic knowledge about HIV/AIDS transmission 
and prevention [1,10]. Published data on treatment outcomes among adolescents and youth 
on ART also show worse adherence, retention and survival in these groups compared with 
older adults [11–17].
Very little information is available, however, on outcomes among youth enrolled in HIV 
care who are not yet eligible for ART. Data are also lacking on the role services targeting 
young people play in improving outcomes among youth in HIV care and on ART. We used 
routinely collected patient-level and clinic-level data from a large, multicountry service 
delivery program in sub-Saharan Africa to compare attrition before and after ART initiation 
between youth and younger adolescents and older adults, and investigated factors associated 
with attrition among youth.
Methods
Study population
The study population included patients aged at least 10 years who enrolled in HIV care 
between January 1, 2005 and September 30, 2010 at 160 HIV care and treatment clinics in 
four sub-Saharan African countries: Kenya (41 clinics), Mozambique (31), Rwanda (41), 
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and Tanzania (47). Patients were followed up until September 30, 2011. ‘Enrolling into HIV 
care’ is defined as the date in which a patient, after testing HIV-positive, attends an HIV 
care clinic for a visit and that date is recorded on the enrollment form. Information is not 
available on the proportion of patients testing HIV-positive at a given clinic who 
subsequently enroll into HIV care. All clinics were receiving technical and financial support 
from ICAP at Columbia University through funding from PEPFAR. Provision of services at 
each clinic was governed by national guidelines.
Data sources
Patient-level data—Patient information routinely collected during each clinic visit 
(described in Table 1) was documented by clinicians on national patient forms. Information 
from these forms was regularly entered into on-site electronic databases by data clerks. 
Information is collected at enrollment and subsequent follow-up visits, with visit frequency 
depending on patient immunologic status and whether they have initiated ART. Data quality 
assessments were done at least annually at each clinic. Each quarter, these data were de-
identified at the site-level, encrypted and transferred to the ICAP-Columbia University 
office in-country, and imported into a common-format database maintained in ICAP-
Columbia University's New York office. Use of these de-identified patient-level data for 
research purposes has been approved by the Columbia University Medical Center IRB and 
ethical review boards in each of the four countries.
Clinic-level data—Data on clinic characteristics were derived cross-sectionally from 
structured assessments completed by ICAP staff in consultation with clinical employees in 
August 2011 and applied retrospectively. These assessments captured information 
regarding: type of setting (urban, semi-urban, and rural); type of facility (primary, 
secondary, and tertiary); year the HIV care and treatment clinic was established; availability 
of adolescent-targeted services, including dedicated clinic hours for adolescents, adolescent 
peer educators, and adolescent support groups; and availability of services likely to be 
utilized by youth, including screening for sexually transmitted infections, condoms and 
hormonal contraceptives, and education on high-risk substance abuse behavior.
Outcome definitions
Pre-antiretroviral therapy outcomes—Cumulative incidence through 1 year after 
enrollment into HIV care of transferring out to another facility before initiating ART, 
recorded death before ART initiation, loss to follow-up before ART initiation, and ART 
initiation was assessed for all patients enrolling into HIV care between January 2005 and 
September 2010. In the pre-ART period, patients were considered lost to follow-up (LTF) 
within 1 year if they were not reported as dead or transferred within 1 year and did not make 
a clinic visit for 1 year with no subsequent visit.
Outcomes after antiretroviral therapy initiation—The subset of patients who 
initiated ART between January 2005 and March 2011 were assessed for outcome status 
through 1 year after ART initiation as follows. Cumulative incidence was calculated as the 
proportion of patients initiating ART who transferred to another facility, were reported 
death, and became LTF. ART patients were considered LTF within 1 year if they were not 
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reported as dead or transferred within 1 year and either were recorded as stopping ART 
treatment or did not make a clinic visit for 6 months with no subsequent visit. All patients 
recorded as stopping ART treatment additionally met the visit date-based definition of LTF.
Attrition—The primary outcome was incidence of attrition through 1 year after enrollment 
in HIV care or ART initiation, depending on the analysis. In both cases, attrition was 
defined as a documented death or LTF.
Statistical analysis
Patients were categorized by age at enrollment into HIV care or ART initiation: 10–14 years 
(young adolescents), 15–24 years (youth), 25–54 years, and at least 55 years. Pre-ARTand 
ART patients who were LTF were censored at 90 and 15 days after their last visit, 
respectively, approximating the midpoint between expected visits.
Age comparison of pre-antiretroviral therapy and post-antiretroviral therapy 
attrition—For all patients, sub-distribution hazard ratios (sHR) for rates of attrition in the 
pre-ART period were compared between age groups treating ART initiation and pre-ART 
attrition as competing risks following the methods outlined by Fine and Grey [18]. Sub-
distribution hazard ratios present the relative hazard of pre-ART attrition through 1 year 
after enrollment into care. Among the subset of patients who initiated ART, hazard ratios 
(HR) for rates of attrition through 1 year after ART initiation were compared between age 
groups using Cox proportional hazards models. Standard errors were calculated using robust 
sandwich estimates for variance to account for within-clinic clustering of patients. Both 
crude and adjusted models were estimated, with adjusted models controlling for sex, 
pregnancy status, year of enrollment/ ART initiation, point of entry into HIV care (e.g., 
PMTCT, VCT, PITC, TB/HIV), CD4+ count at enrollment/ART initiation, TB treatment 
status at enrollment/ART initiation, country, facility type (primary, secondary, tertiary), and 
clinic location (urban, semi-urban, and rural).
Factors associated with attrition among youth—Among youth, we also identified 
patient and clinic-level characteristics associated with pre-ART attrition using the methods 
described above. In addition to examining the association between the factors listed above, 
we assessed the association between the availability of adolescent-targeted services and 
availability of services likely to be utilized by youth described earlier. Not all variables 
measuring availability of adolescent-targeted services had sufficient heterogeneity within 
country, reducing our ability to jointly adjust for country-level effects and availability of 
these services. Consequently, multicountry adjusted models included only those services 
with at least four clinics in each country offering a given service, and at least four clinics in 
each country not offering a given service. Additional analyses investigated the association 
between the remaining adolescent-targeted services and attrition in those countries with 
sufficient heterogeneity.
Results
A total of 312 335 patients at least 10 years of age enrolled into HIV care at the 160 clinics 
during the observation period, including 147 936 who initiated ART. Seventeen percent (53 
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244) of the patients enrolling into care, and 10% (14 844) of the patients initiating ART 
were youth (Table 1). The proportion of all patients at least 10 years of age who were youth 
increased over time from 12% in 2005 to 18% in 2010, and the proportion of patients 
initiating ART who were youth increased from 6% in 2005 to 10% in 2010. Compared with 
the overall population, 10 years and older, youth were more likely to be female (85 vs. 
67%), be referred to care from a PMTCT program (20 vs. 9%), women were more likely to 
be pregnant at enrollment into care (19 vs. 9%) and ART initiation (11 vs. 5%), and 
disproportionately more youth were enrolled in Mozambique (70 vs. 56%). Among the 162 
578 (52%) patients with CD4+ cell count data available at enrollment into HIV care, youth 
had higher median CD4+ cell counts [383 cells/μl; interquartile range (IQR): 202–598] 
comparedwith other age groups [10–14 years: median (IQR) CD4+ = 348 (137–640) cells/μl; 
25–54 years: median (IQR) CD4+ =251 (112–446) cells/μl; ≥55 years: median (IQR) CD4+ 
=232 (113–414) cells/μl]. Among the 100738 (68%) AR patients who had CD4+ cell count 
data available at ART initiation, youth had lower median CD4+ cell counts (184 cells/μl, 
IQR: 92–276) comparedwith younger adolescents median (IQR) CD4+ =204 (82–338) cells/
μl], and higher CD4+ cell counts compared with other adult age groups [25–54 years: 
median (IQR) CD4+ = 161 (78–244) cells/μl; ≥55 years: median (IQR) CD4+ = 169 (93–
250) cells/μl].
One year after enrollment into HIV care, 22% of all patients were retained in pre-ART care, 
42% had initiated ART, 3% had transferred to another facility, 2% were known to have died, 
and 32% were LTF. Compared with the overall population, a substantially higher proportion 
(48%) of youth were LTF, and a smaller proportion of youth initiated ART (25%) (Fig. 1a). 
Among the 140 798 patients initiating ART with at least 1 year of potential follow-up (those 
initiating between January 2005 and September 2010), 70% of all patients were retained on 
ART, 7% transferred to another facility, 5% were known to have died, and 17% were LTF 1 
year after ART initiation. Compared with the overall population, a substantially higher 
proportion of youth were LTF (27%) (Fig. 1b). Among youth, nearly all attrition prior to 
ART initiation (98%) and the vast majority after ART initiation (87%) resulted from LTF.
Attrition before and after antiretroviral therapy initiation by age group
Table 2 presents crude and adjusted estimates of hazard ratios of attrition before and after 
ART initiation between youth and other age groups 1 year after enrollment and ART 
initiation. In adjusted analyses, pre-ART attrition rates 1 year after enrollment into care were 
higher among youth compared with all other age groups: sHR = 2.11 [95% confidence 
interval (CI): 1.88–2.37] for youth vs. young adolescents 10–14 years; sHR = 1.50 (95% CI: 
1.45–1.54) for youth vs. adults aged 25–54; and sHR = 1.64 (95% CI: 1.53–1.75) for youth 
vs. adults aged at least 55 years. One year after ART initiation, youth also experienced 
substantially higher attrition compared with other age groups: HR = 2.45 (95% CI: 2.15–
2.80) for youth vs. younger adolescents 10–14 years; HR = 1.59 (95% CI: 1.52–1.67) for 
youth vs. adults aged 25–54, and HR = 1.62 (95% CI: 1.51–1.74) for youth vs. adults aged at 
least 55 years. Pre-ART and Post-ART LTF was highest among youth compared with other 
age groups in each of the four countries (data not shown).
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Factors associated with attrition among youth
Table 3 presents results of multivariate models investigating factors associated with attrition 
among youth 1 year after enrollment into care and ART initiation. In adjusted pre-ART 
analyses, nonpregnant female youth had slightly lower attrition compared with male youth 
(sHR = 0.90, 95% CI: 0.86–0.94). Compared with youth entering HIV care after testing HIV 
positive through voluntary counseling and testing (VCT), youth enrolling in HIV care 
testing HIV-positive through provider-initiated counseling and testing (PICT) (sHR = 1.3, 
95% CI: 1.2–1.4), TB/HIV clinics (sHR = 1.2, 95% CI: 1.0–1.4), and PMTCT (sHR = 1.3, 
95% IC: 1.2–1.4) had moderately higher attrition in the pre-ART phase. CD4+ cell count at 
enrollment into HIV care was a strong predictor of pre-ART attrition. Youth missing CD4+ 
cell counts at enrollment [relative risk (RR) = 4.0, 95% CI: 3.4–4.8], those with CD4+ cell 
counts more than 350 cells/μl (RR = 2.4, 95% CI: 2.1–2.7), those with CD4+ cell counts 
between 200 and 350 cells/μl (RR = 1.5, 95% CI: 1.4–1.7), and those with CD4+ cell counts 
less than 100 cells/μl at enrollment into HIV care (RR = 1.2, 95% CI: 1.1–1.4) experienced 
higher attrition compared with those enrolling with CD4+ cell counts between 100 and 200 
cells/μl. Youth enrolling into HIV care while on treatment for tuberculosis experienced 
substantially lower attrition in the pre-ART phase compared with youth enrolling not on 
tuberculosis treatment (RR = 0.60, 95% CI: 0.48–0.73). Country was also strongly 
associated with pre-ART attrition: Youth attending clinics in Kenya (RR = 2.7, 95% CI: 
1.9–3.9), Mozambique (RR = 4.3, 95% CI: 3.1–5.9), and Tanzania (RR = 2.2, 1.6–3.3) had 
higher pre-ARTattrition compared with youth attending clinics in Rwanda.
Among clinic-level characteristics assessed, youth attending clinics in semi-urban locations 
experienced moderately higher attrition (RR = 1.24, 95% CI: 1.00–1.53) 1 year after 
enrollment in HIV care compared with youth attending clinics in urban settings. Pre-ART 
attrition was not associated with any of the four adolescent-friendly services assessed with 
sufficient within-country heterogeneity (adolescent-specific clinic hours, screening for 
sexually transmitted infections (STIs), provision of condoms, and provision of hormonal 
contraceptives). In sensitivity analyses restricted to the countries with sufficient 
heterogeneity to examine whether availability of adolescent support groups, availability of 
adolescent peer educators, or education on high-risk substance abusing behavior was 
associated with pre-ART attrition, no significant association was observed (data not shown).
In analyses focusing on attrition among youth 1 year after ART initiation (Table 3), both 
pregnant (RR = 0.85, 95% CI: 0.74–0.97] and nonpregnant (RR = 0.79, 95% CI: 0.73–0.86) 
female youth had lower attrition after ART initiation compared with male youth. Compared 
with those entering HIV care through VCT, youth initiating ART after identification through 
PICT (RR = 1.5, 95% CI: 1.3–1.7) or unknown points of entry (RR = 1.3, 95% CI: 1.0–1.6) 
had higher attrition, while other points of entry (mostly at clinics other than the enrollment 
clinic) were not significantly associated with attrition. One year after ART initiation, youth 
missing CD4+ cell counts at ART initiation (RR = 1.4, 95% CI: 1.2–1.6), and those initiating 
ART with CD4+ cell counts more than 350 cells/μl (RR = 1.2, 95% CI: 0.99–1.5), and CD4+ 
cell counts less than 100 cells/μl (RR = 1.3, 95% CI: 1.2–1.5) had higher attrition than 
patients initiating ART with CD4+ cell counts between 100 and 200 cells/μl. In contrast to 
the pre-ART findings, no difference in attrition after ART initiation was observed depending 
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on tuberculosis treatment status (RR = 1.1, 95% CI: 0.81–1.4). Similar to the results in the 
pre-ART analysis, youth attending clinics in Kenya (RR = 2.5, 95% CI: 1.6–3.8), 
Mozambique (RR = 4.3, 95% CI: 3.3–5.7), and Tanzania (RR = 2.3, 1.5–3.5) had higher 
attrition after ART initiation compared with youth initiating ART in Rwanda.
Among clinic-level factors assessed, there was no significant difference in attrition among 
youth by facility location or type. Among adolescent-friendly services investigated, clinics 
providing condoms had substantially lower attrition after ART initiation (RR = 0.47, 95% 
CI: 0.32–0.70), while those offering adolescent-specific clinic hours experienced moderately 
higher attrition (RR = 1.5, 95% CI: 1.1–2.1). Screening for STIs and provision of hormonal 
contraceptives was not associated with attrition after ART initiation in this analysis. In 
analyses restricted to countries with sufficient variability in availability of adolescent 
support groups, education on high-risk substance abusing behavior (Kenya, Mozambique, 
Rwanda), youth attending clinics offering adolescent support groups had lower attrition (RR 
= 0.73, 95% CI: 0.52–1.0), while those attending clinics offering education on high risk 
substance abusing behavior had higher attrition (RR = 1.3, 95% CI: 1.1–1.5). In Rwanda, the 
sole country with sufficient heterogeneity in the availability of adolescent peer educators, 
attrition was substantially lower at clinics with this service (RR = 0.30, 95% CI: 0.07–1.3), 
although the confidence interval was wide due to the small clinic sample size.
Discussion
As the first multicountry and largest study to date on attrition among HIV-infected youth 
enrolled in HIV care and on ART in sub-Saharan Africa, this study provides important 
insights on program outcomes previously not sufficiently described. Specifically, in addition 
to confirming attrition 1 year after ART initiation is highest among youth compared with all 
other age groups, as shown in other studies [11–17], we found that youth were substantially 
more likely than young adolescents and older adults to die or be lost to follow-up before 
initiating ART. These findings, across a large and diverse study population covering 160 
clinics and four countries in sub-Saharan Africa, held after adjustment for important patient-
level and clinic-level factors.
Eighty-five percent of youth in our study population were female, on par with the sex 
distribution observed among adolescents and young adults in other studies in Africa 
[11,13,19,20]. In our study, 19% of female youth were pregnant at enrollment into HIV care, 
and 20% enrolled through PMTCT, highlighting an important point of entry into clinical 
care for this population. Youth also enrolled into HIV care on average healthier than the 
younger and older adult patient population. Our observation of high attrition among youth 
compared with other age groups after adjustment for baseline markers of health (CD4+ cell 
count and tuberculosis treatment status) suggests that youth may be becoming LTF for 
reasons other than illness. High levels of migration for work [21], and lack of belief in the 
benefits of attending clinic and initiating ART among youth [22], particularly if healthy and 
not yet eligible to initiate ART, are two potential explanations for these findings.
Our findings also indicate a potential benefit of certain services targeting young people on 
attrition, particularly after ART initiation. One hypothesis why such services were not 
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associated with improved pre-ART retention may be that youth lost to follow-up in the pre-
ART phase tend to be lost very soon after enrollment, and may not have had the opportunity 
to engage in the adolescent-friendly services offered at the clinic. After ART initiation, 
youth attending clinics that offered condoms and adolescent support groups experienced 
substantially lower attrition after ART initiation than youth attending clinics not offering 
these services. Further, among youth in Rwanda, those attending clinics with adolescent peer 
educators experienced lower attrition than those attending clinics not offering this service. 
Further analyses, including qualitative analyses, are needed to explore why certain services 
were associated with improved attrition, and certain services were not.
Our study has several important strengths. To our knowledge, it is the largest and sole 
multicountry study investigating attrition among youth enrolled in HIV care and treatment in 
sub-Saharan Africa. Additionally, it is the first to examine outcomes both before and after 
ART initiation, as well as the first to assess whether availability of services targeting young 
people is associated with a decreased risk of attrition among youth. Use of data collected as 
part of routine care, rather than in a research setting, also strengthens our study to investigate 
current conditions at facilities typical of those wherein a majority of individuals seek HIV 
care.
A few limitations must also be noted. A large proportion of patients were missing data on 
CD4+ cell count, an important risk factor for attrition. Given the likelihood that patients 
missing CD4+ cell counts differ systematically from those with complete data, we included a 
‘missing’ CD4+ cell count category in all analyses, rather than imputing these data. Second, 
when investigating the association between services targeting adolescents and attrition, we 
were unable to completely separate out the effect of these services from more general 
between-country differences in attrition because not all services had sufficient within-
country heterogeneity. Analyses described in this article remove countries with insufficient 
heterogeneity from analyses, but caution is warranted in generalizing these results, as we 
cannot rule out that some of the associations between adolescent-targeted services and 
attrition are due to confounding by country effects. Additionally, information on the 
availability of adolescent-friendly services was obtained in 2011, after follow-up of the 
patients in the study. We expect that clinics initiated rather than terminated adolescent-
friendly services during the study period, leading to potential over-estimation of the 
proportion of patients enrolled in HIV care at clinics with such services. This likely biases 
our measures of the association between availability of adolescent-friendly services and 
attrition toward the null, and thus our results should be considered lower bound estimates. 
Further, as data were available on services targeting adolescents rather than youth, we 
assumed that adolescent-friendly services were also used by youth. Finally, as we had no 
information on means of HIV acquisition, we were unable to assess whether risk factors for 
attrition vary between perinatally infected youth and those who acquired HIV behaviorally.
In conclusion, we show that youth accessing HIV care services in 160 clinics across four 
sub-Saharan African countries severely affected by the HIV epidemic are at substantially 
higher risk of attrition than younger adolescents and older adults both before and after ART 
initiation, and that adolescent-friendly services may beneficially impact retention among 
youth after ART initiation. To enhance retention in this important and growing population, 
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we suggest that youth-friendly interventions be implemented and evaluated for their 
effectiveness in improving retention.
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Fig. 1. (a) Patient status 1 year after enrollment into HIV care, by age group. (b) Patient status 1 
year after antiretroviral therapy (ART) initiation, by age group
Lamb et al. Page 11
AIDS. Author manuscript; available in PMC 2015 July 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Lamb et al. Page 12
Ta
bl
e 
1
C
ha
ra
ct
er
ist
ic
s o
f t
he
 p
at
ie
nt
 p
op
ul
at
io
n
En
ro
lli
ng
 in
to
 H
IV
 ca
re
Y
ou
th
 (1
5–
24
)
To
ta
l p
op
ul
at
io
n 
(10
 an
d o
lde
r)
N
%
N
%
To
ta
l
53
24
4
17
%
31
23
35
10
0%
Co
un
try
K
en
ya
57
76
11
%
54
15
2
17
%
M
oz
am
bi
qu
e
37
31
3
70
%
17
47
06
56
%
R
w
an
da
48
65
9%
36
69
2
12
%
Ta
nz
an
ia
52
90
10
%
46
78
5
15
%
En
ro
llm
en
t y
ea
r
20
05
31
60
6%
25
74
8
8%
20
06
72
65
14
%
48
05
2
15
%
20
07
11
03
8
21
%
61
93
0
20
%
20
08
11
80
8
22
%
65
60
0
21
%
20
09
11
40
5
21
%
64
51
0
21
%
20
10
85
68
16
%
46
49
5
15
%
Po
in
t o
f e
nt
ry
PM
TC
T
10
71
9
20
%
27
77
3
9%
V
CT
16
58
4
31
%
10
55
36
34
%
PI
CT
45
31
9%
28
52
6
9%
TB
H
IV
51
6
1%
48
58
2%
O
TH
ER
12
47
9
23
%
80
87
8
26
%
U
nk
no
w
n
84
15
16
%
64
76
4
21
%
Fe
m
al
e
45
05
7
85
%
20
79
33
67
%
Pr
eg
na
nt
 a
t e
nr
ol
lm
en
t
85
55
19
%
19
51
1
9%
CD
4+
 
(ce
lls
/μl
) a
t e
nro
llm
en
t
<
10
0
30
71
6%
34
20
8
11
%
10
1–
20
0
29
82
6%
29
14
4
9%
20
1–
35
0
50
56
9%
36
64
5
12
%
>
35
0
13
29
8
25
%
62
58
1
20
%
M
iss
in
g
28
83
7
54
%
14
97
57
48
%
W
H
O
 st
ag
e 
at
 e
nr
ol
lm
en
t
I
14
07
9
26
%
61
70
7
20
%
AIDS. Author manuscript; available in PMC 2015 July 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Lamb et al. Page 13
En
ro
lli
ng
 in
to
 H
IV
 ca
re
Y
ou
th
 (1
5–
24
)
To
ta
l p
op
ul
at
io
n 
(10
 an
d o
lde
r)
N
%
N
%
II
79
51
15
%
56
44
9
18
%
II
I
10
54
5
20
%
84
87
6
27
%
IV
24
03
5%
21
75
6
7%
M
iss
in
g
18
26
6
34
%
87
54
7
28
%
O
n 
TB
 tr
ea
tm
en
t a
t e
nr
ol
lm
en
t
95
6
2%
97
25
3%
In
iti
at
in
g 
A
RT
Y
ou
th
 (1
5–
24
)
To
ta
l p
op
ul
at
io
n 
(10
 an
d o
lde
r)
N
%
N
%
To
ta
l
14
84
4
10
%
14
79
36
10
0%
A
RT
 in
iti
at
io
n 
ye
ar
20
05
55
1
4%
85
38
6%
20
06
16
50
11
%
19
92
9
13
%
20
07
31
10
21
%
28
27
4
19
%
20
08
31
97
22
%
29
96
0
20
%
20
09
32
75
22
%
31
21
6
21
%
20
10
28
14
19
%
27
44
6
19
%
20
11
24
7
2%
25
73
2%
Fe
m
al
e
12
19
3
82
%
95
04
3
64
%
Pr
eg
na
nt
 a
t A
RT
 in
iti
at
io
n
13
79
11
%
47
97
5%
CD
4+
 
(ce
lls
/μl
) a
t A
RT
 in
itia
tio
n
<
10
0
26
35
18
%
31
15
6
21
%
10
1–
20
0
27
76
19
%
31
50
4
21
%
20
1–
35
0
32
53
22
%
30
44
0
21
%
>
35
0
11
07
7%
76
38
5%
M
iss
in
g
50
73
34
%
47
19
8
32
%
W
H
O
 st
ag
e 
at
 A
RT
 in
iti
at
io
n
I
14
76
10
%
11
31
0
8%
II
15
68
11
%
18
54
9
13
%
II
I
36
73
25
%
39
49
7
27
%
IV
11
11
7%
13
20
4
9%
AIDS. Author manuscript; available in PMC 2015 July 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Lamb et al. Page 14
En
ro
lli
ng
 in
to
 H
IV
 ca
re
Y
ou
th
 (1
5–
24
)
To
ta
l p
op
ul
at
io
n 
(10
 an
d o
lde
r)
N
%
N
%
M
iss
in
g
70
16
47
%
65
37
6
44
%
O
n 
TB
 tr
ea
tm
en
t a
t A
RT
 in
iti
at
io
n
23
2
2%
30
87
2%
AIDS. Author manuscript; available in PMC 2015 July 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Lamb et al. Page 15
Ta
bl
e 
2
H
az
ar
d 
ra
tio
s f
or
 p
re
-a
nt
ir
et
ro
vi
ra
l t
he
ra
py
 a
nd
 p
os
t-a
nt
ir
et
ro
vi
ra
l t
he
ra
py
 a
ttr
iti
on
 a
fte
r 
on
e 
ye
ar
, b
y 
ag
e 
ca
te
go
ry
Pr
e-
an
tir
et
ro
vi
ra
l t
he
ra
py
 a
ttr
iti
on
A
ttr
iti
on
 a
fte
r 
an
tir
et
ro
vi
ra
l t
he
ra
py
 in
iti
at
io
n
C
ru
de
A
dju
ste
da
C
ru
de
A
dju
ste
db
A
ge
 (y
ea
rs)
N
%
sH
R
c
95
%
 C
I
sH
R
c
95
%
 C
I
N
%
H
R
95
%
C
I
H
R
95
%
 C
I
10
–1
4
37
94
1%
0.
63
(0.
55
–0
.71
)
0.
71
(0.
64
–0
.79
)
21
27
1%
0.
61
(0.
53
–0
.70
)
0.
65
(0.
58
–0
.73
)
15
–2
4
53
24
4
17
%
1.
77
(1.
69
–1
.85
)
1.
50
(1.
45
–1
.54
)
14
 8
44
10
%
1.
55
(1.
49
–1
.63
)
1.
59
(1.
52
–1
.67
)
25
–5
4
24
04
40
77
%
R
ef
er
en
ce
12
28
31
83
%
R
ef
er
en
ce
≥5
5
48
57
5%
0.
92
(0.
87
–0
.98
)
0.
91
(0.
87
–0
.96
)
81
34
5%
1.
04
(0.
98
–1
.10
)
0.
98
(0.
93
–1
.04
)
a
A
dju
ste
d f
or 
sex
, p
reg
na
nc
y s
tat
us,
 po
int
 of
 en
try
 in
to 
car
e, 
TB
 tre
atm
en
t s
tat
us 
at 
en
rol
lm
en
t, C
D4
+
 
co
u
n
t a
t e
nr
ol
lm
en
t, 
ye
ar
 o
f e
nr
ol
lm
en
t, 
co
un
try
, f
ac
ili
ty
 ty
pe
 (p
rim
ary
 vs
. s
ec
on
da
ry/
ter
tia
ry)
 an
d 
fa
ci
lit
y 
lo
ca
tio
n 
(ur
ba
n, 
sem
i-u
rba
n, 
rur
al)
.
b A
dju
ste
d f
or 
sex
, p
reg
na
nc
y s
tat
us,
 po
int
 of
 en
try
 in
to 
car
e, 
TB
 tre
atm
en
t s
tat
us 
at 
AR
T i
nit
iat
ion
, C
D4
+
 
co
u
n
t a
t A
RT
 in
iti
at
io
n,
 y
ea
r o
f A
RT
 in
iti
at
io
n,
 c
ou
nt
ry
, f
ac
ili
ty
 ty
pe
 (p
rim
ary
 vs
. s
ec
on
da
ry/
te
rt
ia
ry
) a
nd
 fa
cil
ity
 lo
ca
tio
n (
urb
an
, s
em
i-u
rba
n, 
rur
al)
.
c S
ub
-d
ist
rib
ut
io
n 
ha
za
rd
 ra
tio
 a
cc
ou
nt
in
g 
fo
r A
RT
 in
iti
at
io
n 
as
 a
 c
om
pe
tin
g 
ris
k 
fo
r p
re
-A
RT
 a
ttr
iti
on
.
AIDS. Author manuscript; available in PMC 2015 July 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Lamb et al. Page 16
Ta
bl
e 
3
M
ul
tiv
ar
ia
te
 r
eg
re
ss
io
n:
 fa
ct
or
s a
ss
oc
ia
te
d 
w
ith
 p
re
-a
nt
ir
et
ro
vi
ra
l t
he
ra
py
 a
nd
 p
os
t-a
nt
ir
et
ro
vi
ra
l t
he
ra
py
 a
ttr
iti
on
 a
fte
r 
1 
ye
ar
sH
R
 fo
r 
pr
e-
an
tir
et
ro
vr
al
 th
er
ap
y 
at
tr
iti
on
a
H
R
 fo
r 
an
tir
et
ro
vr
al
 th
er
ap
y 
at
tr
iti
on
b
C
ru
de
A
dju
ste
d
C
ru
de
A
dju
ste
d
R
R
95
%
 C
I
R
R
95
%
 C
I
R
R
95
%
 C
I
R
R
95
%
 C
I
Pr
eg
na
nt
 w
om
en
1.
23
(1.
10
–1
.38
)
0.
97
(0.
88
–1
.08
)
0.
90
(0.
77
–1
.04
)
0.
85
(0.
74
–0
.97
)
N
on
pr
eg
na
nt
 w
om
en
0.
98
(0.
93
–1
.03
)
0.
90
(0.
86
–0
.94
)
0.
80
(0.
73
–0
.89
)
0.
79
(0.
73
–0
.86
)
M
en
R
ef
er
en
ce
En
ro
llm
en
t y
ea
r/a
nt
ire
tro
vi
ra
l t
he
ra
py
 in
iti
at
io
n 
ye
ar
20
11
0.
65
(0.
4–
1.0
5)
0.
65
(0.
39
–1
.08
)
20
10
1.
01
(0.
81
–1
.25
)
1.
02
(0.
84
–1
.24
)
1.
29
(0.
95
–1
.76
)
1.
26
(0.
9–
1.7
5)
20
09
1.
09
(0.
88
–1
.33
)
1.
14
(0.
95
–1
.38
)
1.
38
(1.
05
–1
.82
)
1.
29
(0.
95
–1
.77
)
20
08
1.
14
(0.
92
–1
.40
)
1.
19
(0.
99
–1
.43
)
1.
62
(1.
2–
2.2
)
1.
50
(1.
06
–2
.12
)
20
07
1.
09
(0.
91
–1
.30
)
1.
15
(0.
99
–1
.34
)
1.
45
(1.
08
–1
.95
)
1.
31
(0.
95
–1
.81
)
20
06
1.
04
(0.
88
–1
.22
)
1.
06
(0.
92
–1
.22
)
1.
26
(0.
98
–1
.61
)
1.
16
(0.
89
–1
.51
)
20
05
R
ef
er
en
ce
O
n 
TB
 tr
ea
tm
en
t a
t e
nr
ol
lm
en
t/a
nt
ire
tro
vi
ra
l t
he
ra
py
 in
iti
at
io
n
0.
56
(0.
47
–0
.67
)
0.
60
(0.
48
–0
.73
)
1.
08
(0.
79
–1
.47
)
1.
05
(0.
81
–1
.35
)
Po
in
t o
f e
nt
ry
 in
to
 H
IV
 c
ar
e
PM
TC
T
1.
42
(1.
25
–1
.60
)
1.
26
(1.
15
–1
.38
)
1.
00
(0.
84
–1
.19
)
1.
07
(0.
89
–1
.28
)
PI
CT
1.
41
(1.
21
–1
.64
)
1.
27
(1.
13
–1
.42
)
1.
53
(1.
27
–1
.83
)
1.
46
(1.
26
–1
.68
)
TB
/H
1V
1.
15
(0.
98
–1
.34
)
1.
17
(1.
01
–1
.36
)
1.
16
(0.
9–
1.5
)
1.
11
(0.
89
–1
.4)
O
th
er
 c
lin
ic
1.
09
(0.
95
–1
.25
)
0.
94
(0.
86
–1
.03
)
1.
20
(0.
89
–1
.61
)
0.
89
(0.
77
–1
.03
)
U
nk
no
w
n
1.
27
(1.
10
–1
.46
)
1.
23
(1.
13
–1
.34
)
1.
30
(0.
99
–1
.71
)
1.
27
(1.
03
–1
.57
)
V
CT
R
ef
er
en
ce
CD
4+
 
ce
ll 
co
un
t (
ce
lls
/μl
) a
t e
nro
llm
en
t/a
nti
ret
rov
ira
l th
era
py
 
in
iti
at
io
n
M
iss
in
g
4.
16
3.
48
–4
.9
7)
4.
04
3.
42
–4
.7
8)
1.
42
(1.
13
–1
.8)
1.
36
(1.
15
–1
.61
)
>
35
0
2.
13
(1.
83
–2
.47
)
2.
37
2.
05
–2
.7
3)
1.
29
(1.
1–
1.5
1)
1.
20
(0.
99
–1
.45
)
20
0–
35
0
1.
50
(1.
34
–1
.67
)
1.
52
(1.
36
–1
.71
)
0.
86
(0.
77
–0
.96
)
0.
96
(0.
88
–1
.05
)
10
0–
20
0
R
ef
er
en
ce
<
10
0
1.
20
(1.
06
–1
.36
)
1.
22
(1.
08
–1
.36
)
1.
34
(1.
22
–1
.46
)
1.
33
(1.
21
–1
.46
)
Fa
ci
lit
y-
le
ve
l s
er
vi
ce
s
Co
un
try
K
en
ya
3.
81
2.
78
–5
.0
9)
2.
72
(1.
91
 –3
.90
)
3.
33
2.
23
–5
.2
1)
2.
46
(1.
58
–3
.82
)
AIDS. Author manuscript; available in PMC 2015 July 28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Lamb et al. Page 17
sH
R
 fo
r 
pr
e-
an
tir
et
ro
vr
al
 th
er
ap
y 
at
tr
iti
on
a
H
R
 fo
r 
an
tir
et
ro
vr
al
 th
er
ap
y 
at
tr
iti
on
b
C
ru
de
A
dju
ste
d
C
ru
de
A
dju
ste
d
R
R
95
%
 C
I
R
R
95
%
 C
I
R
R
95
%
 C
I
R
R
95
%
 C
I
M
oz
am
bi
qu
e
4.
89
3.
65
–6
.5
5)
4.
28
3.
13
–5
.8
5)
4.
73
3.
53
–6
.3
2)
4.
29
(3.
27
–5
.65
)
Ta
nz
an
ia
3.
76
2.
78
–5
.0
9)
2.
24
(1.
55
–3
.25
)
3.
77
2.
89
–4
.9
2)
2.
27
(1.
49
–3
.46
)
R
w
an
da
R
ef
er
en
ce
Fa
ci
lit
y 
ty
pe
Pr
im
ar
y
1.
08
(0.
90
–1
.30
)
1.
09
(0.
96
–1
.25
)
0.
86
(0.
67
–1
.11
)
0.
89
(0.
75
–1
.06
)
Se
co
nd
ar
y/
 T
er
tia
ry
R
ef
er
en
ce
Cl
in
ic
 lo
ca
tio
n
R
ur
al
0.
97
(0.
75
–1
.26
)
0.
97
(0.
84
–1
.12
)
0.
79
(0.
57
–1
.08
)
0.
86
(0.
69
–1
.09
)
Se
m
i-u
rb
an
0.
93
(0.
77
–1
.13
)
1.
24
(1.
00
–1
.53
)
0.
84
(0.
62
–1
.14
)
1.
12
(0.
79
–1
.58
)
U
rb
an
R
ef
er
en
ce
A
do
le
sc
en
t-s
pe
ci
fic
 se
rv
ic
es
 
A
do
le
sc
en
t-s
pe
ci
fic
 c
lin
ic
 h
ou
rs
1.
01
(0.
84
–1
.22
)
1.
06
(0.
89
–1
.27
)
1.
07
(0.
79
–1
.44
)
1.
48
(1.
05
–2
.08
)
 
A
do
le
sc
en
t p
ee
r e
du
ca
to
rs
c
0.
73
(0.
44
–1
.21
)
0.
66
(0.
45
–0
.97
)
 
A
do
le
sc
en
t s
up
po
rt 
gr
ou
ps
c
0.
82
(0.
58
–1
.17
)
1.
07
(0.
68
–1
.69
)
O
th
er
 se
rv
ic
es
 u
til
iz
ed
 b
y 
yo
ut
h
 
Sc
re
en
in
g 
fo
r S
Tl
s
0.
99
(0.
79
–1
.24
)
1.
27
(1.
03
–1
.56
)
0.
88
(0.
67
–1
.16
)
1.
15
(0.
91
–1
.44
)
 
Pr
ov
isi
on
 o
f c
on
do
m
s
1.
06
(0.
88
–1
.28
)
0.
82
(0.
63
–1
.07
)
0.
88
(0.
68
–1
.14
)
0.
47
(0.
32
–0
.7)
 
H
or
m
on
al
 c
on
tra
ce
pt
iv
es
1.
09
(0.
89
–1
.34
)
1.
01
(0.
81
–1
.26
)
0.
97
(0.
75
–1
.24
)
1.
13
(0.
87
–1
.47
)
 
Ed
uc
at
io
n 
on
 h
ig
h 
ris
k 
su
bs
ta
nc
e-
ab
us
in
g 
be
ha
vi
or
c
1.
08
(0.
81
–1
.44
)
1.
01
(0.
74
–1
.37
)
CI
, c
on
fid
en
ce
 in
te
rv
al
; H
R,
 h
az
ar
d 
ra
tio
; R
R,
 re
la
tiv
e 
ris
k;
 sH
R,
 su
b-
di
vi
sio
n 
ha
za
rd
 ra
tio
.
a
Su
b-
di
str
ib
ut
io
n 
ha
za
rd
 ra
tio
s a
cc
ou
nt
in
g 
fo
r w
ith
in
-c
lin
ic
 c
lu
ste
rin
g 
es
tim
at
in
g 
th
e 
re
la
tiv
e 
ha
za
rd
 o
f p
re
-A
RT
 a
ttr
iti
on
 1
 y
ea
r a
fte
r e
nr
ol
lm
en
t. 
A
dju
ste
d r
ati
os 
pre
sen
ted
 ad
jus
t fo
r a
ll o
the
r v
ari
ab
les
 in
 
th
e 
ta
bl
e.
b P
ro
po
rti
on
al
 h
az
ar
ds
 m
od
el
 re
gr
es
sio
n 
ac
co
un
tin
g 
fo
r w
ith
in
-c
lin
ic
 c
lu
ste
rin
g 
us
ed
 to
 e
sti
m
at
e 
ra
te
 ra
tio
s f
or
 L
TF
 1
 y
ea
r a
fte
r A
RT
 in
iti
at
io
n.
 A
dju
ste
d r
ati
os 
pre
sen
ted
 ad
jus
t fo
r a
ll o
the
r v
ari
ab
les
 in
 th
e 
ta
bl
e.
c T
he
se
 th
re
e 
ad
ol
es
ce
nt
-fr
ie
nd
ly
 se
rv
ic
es
 w
er
e 
no
t a
ss
es
se
d 
in
 m
ul
tic
ou
nt
ry
 a
dju
ste
d m
od
els
 du
e t
o l
ack
 of
 su
ffi
cie
nt 
wi
thi
n-c
ou
ntr
y h
ete
rog
en
eit
y.
AIDS. Author manuscript; available in PMC 2015 July 28.
